A review of clinical safety data for sumatriptan nasal powder administered by a breath powered exhalation delivery system in the acute treatment of migraine
Sign Up to like & getrecommendations! Published in 2018 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2018.1390563
Abstract: ABSTRACT Introduction: AVP-825 (sumatriptan nasal powder) is an FDA-approved intranasal medication delivery system containing low-dose sumatriptan powder for acute treatment of migraine with or without aura in adults. AVP-825 utilizes unique nasal anatomy features to… read more here.
Keywords: migraine; sumatriptan; delivery; nasal ... See more keywords